Articles producció científica> Medicina i Cirurgia

Circulating miRNAs as Potential Biomarkers for Celiac Disease Development

  • Dades identificatives

    Identificador: imarina:9242326
    Autors:
    Tan ILCoutinho de Almeida RModderman RStachurska ADekens JBarisani DMeijer CRRoca MMartinez-Ojinaga EShamir RAuricchio RKorponay-Szabó IRCastillejo GSzajewska HKoletzko SZhernakova AKumar VLi YVisschedijk MCWeersma RKTroncone RMearin MLWijmenga CJonkers IWithoff S
    Resum:
    Background & Aims: Celiac disease (CeD), an immune-mediated disease with enteropathy triggered by gluten, affects ~1% of the general European population. Currently, there are no biomarkers to predict CeD development. MicroRNAs (miRNAs) are short RNAs involved in post-transcriptional gene regulation, and certain disease- and stage-specific miRNA profiles have been found previously. We aimed to investigate whether circulating miRNAs can predict the development of CeD. Methods: Using next-generation miRNA-sequencing, we determined miRNAs in >200 serum samples from 53 participants of the PreventCD study, of whom 33 developed CeD during follow-up. Following study inclusion at 3 months of age, samples were drawn at predefined ages, diagnosis (first anti-transglutaminase antibody (TGA) positivity or diagnostic biopsy) and after the start of a gluten-free diet (GFD). This allowed identification of circulating miRNAs that are deregulated before TGA positivity. For validation of the biomarkers for CeD and GFD response, two additional cohorts were included in subsequent meta-analyses. Additionally, miRNAs were measured in duodenal biopsies in a case-control cohort. Results: 53 circulating miRNAs were increased (27) or decreased (26) in CeD versus controls. We assessed specific trends in these individual miRNAs in the PreventCD cohort by grouping the pre-diagnostic samples of the CeD patients (all had negative TGA) by how close to seroconversion (first sample positive TGA) the samples were taken. 8/53 miRNAs differed significantly between controls and samples taken <1 year before TGA positivity: miR-21-3p, miR-374a-5p, 144-3p, miR-500a-3p, miR-486-3p let-7d-3p, let-7e-5p and miR-3605-3p. 6/26 downregulated miRNAs reconstituted upon GFD, including miR-150-5p/-3p, whereas no upregula
  • Altres:

    Autor segons l'article: Tan IL; Coutinho de Almeida R; Modderman R; Stachurska A; Dekens J; Barisani D; Meijer CR; Roca M; Martinez-Ojinaga E; Shamir R; Auricchio R; Korponay-Szabó IR; Castillejo G; Szajewska H; Koletzko S; Zhernakova A; Kumar V; Li Y; Visschedijk MC; Weersma RK; Troncone R; Mearin ML; Wijmenga C; Jonkers I; Withoff S
    Departament: Medicina i Cirurgia
    Autor/s de la URV: Castillejo De Villasante, Gemma
    Paraules clau: Small rna sequencing Pre-diagnostic marker Pre-clinical marker Diagnosis Celiac disease Autoimmunity society profiles pre-diagnostic marker pre-clinical marker microrna management il-15 guidelines expression disorders celiac disease cancer autoimmunity
    Resum: Background & Aims: Celiac disease (CeD), an immune-mediated disease with enteropathy triggered by gluten, affects ~1% of the general European population. Currently, there are no biomarkers to predict CeD development. MicroRNAs (miRNAs) are short RNAs involved in post-transcriptional gene regulation, and certain disease- and stage-specific miRNA profiles have been found previously. We aimed to investigate whether circulating miRNAs can predict the development of CeD. Methods: Using next-generation miRNA-sequencing, we determined miRNAs in >200 serum samples from 53 participants of the PreventCD study, of whom 33 developed CeD during follow-up. Following study inclusion at 3 months of age, samples were drawn at predefined ages, diagnosis (first anti-transglutaminase antibody (TGA) positivity or diagnostic biopsy) and after the start of a gluten-free diet (GFD). This allowed identification of circulating miRNAs that are deregulated before TGA positivity. For validation of the biomarkers for CeD and GFD response, two additional cohorts were included in subsequent meta-analyses. Additionally, miRNAs were measured in duodenal biopsies in a case-control cohort. Results: 53 circulating miRNAs were increased (27) or decreased (26) in CeD versus controls. We assessed specific trends in these individual miRNAs in the PreventCD cohort by grouping the pre-diagnostic samples of the CeD patients (all had negative TGA) by how close to seroconversion (first sample positive TGA) the samples were taken. 8/53 miRNAs differed significantly between controls and samples taken <1 year before TGA positivity: miR-21-3p, miR-374a-5p, 144-3p, miR-500a-3p, miR-486-3p let-7d-3p, let-7e-5p and miR-3605-3p. 6/26 downregulated miRNAs reconstituted upon GFD, including miR-150-5p/-3p, whereas no upregulated miRNAs were downregulated upon GFD. 15/53 biomarker candidates also differed between CeD biopsies and controls, with a concordant direction, indicating that these circulating miRNAs might originate from the intestine. Conclusions: We identified 53 circulating miRNAs that are potential early biomarkers for CeD, of which several can be detected more than a year before TGA positivity and some start to normalize upon GFD. Copyright © 2021 Tan, Coutinho de Almeida, Modderman, Stachurska, Dekens, Barisani, Meijer, Roca, Martinez-Ojinaga, Shamir, Auricchio, Korponay-Szabó, Castillejo, Szajewska, Koletzko, Zhernakova, Kumar, Li, Visschedijk, Weersma, Troncone, Mearin, Wijmenga, Jonkers and Withoff.
    Àrees temàtiques: Zootecnia / recursos pesqueiros Saúde coletiva Química Odontología Nutrição Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar Immunology and allergy Immunology Farmacia Engenharias iii Engenharias ii Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Biotecnología Biodiversidade
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Adreça de correu electrònic de l'autor: gemma.castillejo@urv.cat
    Data d'alta del registre: 2024-07-27
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://www.frontiersin.org/articles/10.3389/fimmu.2021.734763/full
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referència a l'article segons font original: Frontiers In Immunology. 12
    Referència de l'ítem segons les normes APA: Tan IL; Coutinho de Almeida R; Modderman R; Stachurska A; Dekens J; Barisani D; Meijer CR; Roca M; Martinez-Ojinaga E; Shamir R; Auricchio R; Korponay (2021). Circulating miRNAs as Potential Biomarkers for Celiac Disease Development. Frontiers In Immunology, 12(), -. DOI: 10.3389/fimmu.2021.734763
    DOI de l'article: 10.3389/fimmu.2021.734763
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2021
    Tipus de publicació: Journal Publications
  • Paraules clau:

    Immunology,Immunology and Allergy
    Small rna sequencing
    Pre-diagnostic marker
    Pre-clinical marker
    Diagnosis
    Celiac disease
    Autoimmunity
    society
    profiles
    pre-diagnostic marker
    pre-clinical marker
    microrna
    management
    il-15
    guidelines
    expression
    disorders
    celiac disease
    cancer
    autoimmunity
    Zootecnia / recursos pesqueiros
    Saúde coletiva
    Química
    Odontología
    Nutrição
    Medicina veterinaria
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    Immunology and allergy
    Immunology
    Farmacia
    Engenharias iii
    Engenharias ii
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Ciência de alimentos
    Biotecnología
    Biodiversidade
  • Documents:

  • Cerca a google

    Search to google scholar